<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357822</url>
  </required_header>
  <id_info>
    <org_study_id>COST study</org_study_id>
    <nct_id>NCT03357822</nct_id>
  </id_info>
  <brief_title>A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B</brief_title>
  <acronym>COST</acronym>
  <official_title>A Real-World Study of Sequential Combination Therapy With Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the prospective real-world study is to evaluate whether sequential combination&#xD;
      therapy with pegylated interferon plus entecavir/tenofovir could induce higher rates of HBsAg&#xD;
      loss in nucleoside-treated patients with chronic hepatitis B compared to continuous&#xD;
      nucleoside treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patents who were treated with NA at least one year and achieved hepatitis B virus (HBV) DNA&#xD;
      suppression and HBsAg level&lt;3000 international unit (IU) /mL are enrolled in this study, they&#xD;
      are assigned into two groups, in group I, patients will receive pegylated interferon plus&#xD;
      entecavir/tenofovir for 48/72/96 weeks, in group II, patients will receive&#xD;
      entecavir/tenofovir for 96 weeks. HBsAg loss rates at the end of treatment and sustained&#xD;
      response at the end of follow up will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">July 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg loss rate</measure>
    <time_frame>at week 48</time_frame>
    <description>Percentages of patients who achieve HBsAg loss at week 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss rate</measure>
    <time_frame>at week 72</time_frame>
    <description>Percentages of patients who achieve HBsAg loss at week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss rate</measure>
    <time_frame>at week 96</time_frame>
    <description>Percentages of patients who achieve HBsAg loss at week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg level</measure>
    <time_frame>at week 48</time_frame>
    <description>Dynamic change in HBsAg level from baseline to week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg level</measure>
    <time_frame>at week 72</time_frame>
    <description>Dynamic change in HBsAg level from baseline to week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg level</measure>
    <time_frame>at week 96</time_frame>
    <description>Dynamic change in HBsAg level from baseline to week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sustained HBsAg loss rate</measure>
    <time_frame>at week 120</time_frame>
    <description>Percentages of patients who achieve HBsAg loss at week 120</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decline in HBsAg level</measure>
    <time_frame>at week 48</time_frame>
    <description>Decline in HBsAg level from baseline to week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decline in HBsAg level</measure>
    <time_frame>at week 72</time_frame>
    <description>Decline in HBsAg level from baseline to week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decline in HBsAg level</measure>
    <time_frame>at week 96</time_frame>
    <description>Decline in HBsAg level from baseline to week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAb appearance rate</measure>
    <time_frame>at week 48</time_frame>
    <description>Percentages of HBsAb appearance at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAb appearance rate</measure>
    <time_frame>at week 72</time_frame>
    <description>Percentages of HBsAb appearance at week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAb appearance rate</measure>
    <time_frame>at week 96</time_frame>
    <description>Percentages of HBsAb appearance at week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAb seroconversion rate</measure>
    <time_frame>at week 48</time_frame>
    <description>Percentages of HBsAb seroconversion at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAb seroconversion rate</measure>
    <time_frame>at week 72</time_frame>
    <description>Percentages of HBsAb seroconversion at week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAb seroconversion rate</measure>
    <time_frame>at week 96</time_frame>
    <description>Percentages of HBsAb seroconversion at week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss rate</measure>
    <time_frame>at week 48</time_frame>
    <description>Percentages of HBeAg loss in the HBeAg-positive patients at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss rate</measure>
    <time_frame>at week 72</time_frame>
    <description>Percentages of HBeAg loss in the HBeAg-positive patients at week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss rate</measure>
    <time_frame>at week 96</time_frame>
    <description>Percentages of HBeAg loss in the HBeAg-positive patients at week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion rate</measure>
    <time_frame>at week 48</time_frame>
    <description>Percentages of HBeAg seroconversion in the HBeAb-negative patients at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion rate</measure>
    <time_frame>at week 72</time_frame>
    <description>Percentages of HBeAg seroconversion in the HBeAb-negative patients at week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion rate</measure>
    <time_frame>at week 96</time_frame>
    <description>Percentages of HBeAg seroconversion in the HBeAb-negative patients at week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HBV DNA level &lt;1000 copies/mL</measure>
    <time_frame>at week 96</time_frame>
    <description>Percentages of HBV DNA level &lt;1000 copies/mL at week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of alanine aminotransferase (ALT) normalization</measure>
    <time_frame>at week 96</time_frame>
    <description>Percentages of ALT normalization at week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of progression to cirrhosis</measure>
    <time_frame>at week 120</time_frame>
    <description>The rate of progression to cirrhosis at week 120</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of hepatocarcinoma</measure>
    <time_frame>at week 120</time_frame>
    <description>The incidence rate of hepatocarcinoma at week 120</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Sequential combination therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with pegylated Interferon (180ug, subcutaneously, once a week) plus entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 48/72/96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nucleoside therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are treated with entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon</intervention_name>
    <description>180ug Pegylated interferon is injected subcutaneously once a week</description>
    <arm_group_label>Sequential combination therapy group</arm_group_label>
    <other_name>Pegylated interferon (PegIFN)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>0.5mg entecavir is orally taken every day</description>
    <arm_group_label>Nucleoside therapy group</arm_group_label>
    <arm_group_label>Sequential combination therapy group</arm_group_label>
    <other_name>Entecavir (ETV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>300mg tenofovir is orally taken every day</description>
    <arm_group_label>Nucleoside therapy group</arm_group_label>
    <arm_group_label>Sequential combination therapy group</arm_group_label>
    <other_name>Tenofovir disoproxil fumarate (TDF)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients from 18 to 65 years of age;&#xD;
&#xD;
          2. HBsAg positive, entecavir and or adefovir dipivoxil are used at least 1 year including&#xD;
             patients with nucleotides or nucleoside resistance history;&#xD;
&#xD;
          3. Before nucleotides or nucleosides treatment, ALT &gt; 2 upper limit of normal value&#xD;
             (ULN), HBV DNA &gt;10000 copies/ml, HBsAg positive;&#xD;
&#xD;
          4. Serum HBV DNA ≤ 500 copies/ml;&#xD;
&#xD;
          5. HBsAg&lt;3000 IU/ml;&#xD;
&#xD;
          6. HBsAg positive;&#xD;
&#xD;
          7. Negative urine or serum pregnancy test (for women of childbearing potential)&#xD;
             documented within the 24-hour period prior to the first dose of test drug;&#xD;
&#xD;
          8. Absence of cirrhosis confirmed by ultrasonic test;&#xD;
&#xD;
          9. Agree to participate in the study and sign the patient informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HBV DNA &gt; 500 copies/ml;&#xD;
&#xD;
          2. Other antiviral, anti-neoplastic or immunomodulatory treatment (including supra&#xD;
             physiologic doses of steroids and radiation) 6 months prior to the first dose of&#xD;
             randomized treatment (except for 7 days of acyclovir for herpetic lesions more than 1&#xD;
             month prior to first administration of randomized treatment). Patients who are&#xD;
             expected to need systemic antiviral therapy other than that provided by the study at&#xD;
             any time during their participation are also excluded;&#xD;
&#xD;
          3. Women with ongoing pregnancy or breast-feeding;&#xD;
&#xD;
          4. Co-infection with active hepatitis A, hepatitis C, hepatitis D(Those hospitals which&#xD;
             have the ability to do the test will do) and/or human immunodeficiency virus (HIV);&#xD;
&#xD;
          5. ALT &gt;10 ULN;&#xD;
&#xD;
          6. Evidence of decompensated liver disease (Child-Pugh score &gt; 5). Child-Pugh &gt; 5 means,&#xD;
             if one of the following 5 conditions are met, the patient has to be excluded:&#xD;
&#xD;
          7. one of the following 5 conditions are met, the patient has to be excluded:&#xD;
&#xD;
          8. Serum albumin &lt; 3.5 g/L;&#xD;
&#xD;
          9. Prothrombin time &gt; 3 seconds prolonged;&#xD;
&#xD;
         10. Serum bilirubin &gt; 34 µ mol/L;&#xD;
&#xD;
         11. History of encephalopathy;&#xD;
&#xD;
         12. History of variceal bleeding;&#xD;
&#xD;
         13. Ascites;&#xD;
&#xD;
         14. History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic&#xD;
             liver disease, alcoholic liver disease, toxin exposures, thalassemia);&#xD;
&#xD;
         15. Signs or symptoms of hepatocellular carcinoma, patients with a value of&#xD;
             alpha-fetoprotein &gt; 100 ng/mL are excluded, unless stability (less than 10% increase)&#xD;
             has been documented over at least the previous 3 months. Patients with values &lt; 20&#xD;
             ng/mL but &gt; 100 ng/mL may be enrolled, if hepatic neoplasia has been excluded by liver&#xD;
             imaging;&#xD;
&#xD;
         16. Neutrophil count &lt; 1500 cells/mm3 or platelet count &lt;90,000 cells/mm3 at screening;&#xD;
&#xD;
         17. Hemoglobin &lt; 11.5 g/dL for females and &lt;12.5 g/dL for men;&#xD;
&#xD;
         18. Serum creatinine level &gt; 1.5 ULN in screening period.&#xD;
&#xD;
         19. Phosphorus &lt; 0.65 mmol/L;&#xD;
&#xD;
         20. antinuclear antibody (ANA) &gt; 1:100;&#xD;
&#xD;
         21. History of severe psychiatric disease, especially depression. Severe psychiatric&#xD;
             disease is defined as treatment with an antidepressant medication or a major&#xD;
             tranquilizer at therapeutic doses for major depression or psychosis, respectively, for&#xD;
             at least 3 months at any previous time or any history of the following: a suicidal&#xD;
             attempt hospitalization for psychiatric disease, or a period of disability due to a&#xD;
             psychiatric disease;&#xD;
&#xD;
         22. History of a severe seizure disorder or current anticonvulsant use;&#xD;
&#xD;
         23. History of immunologically mediated disease, (e.g., inflammatory bowel disease,&#xD;
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia,&#xD;
             scleroderma, rheumatoid arthritis etc.);&#xD;
&#xD;
         24. History of chronic pulmonary disease associated with functional limitation;&#xD;
&#xD;
         25. Diseases that interferon and nucleotides or nucleosides are not suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qin Ning</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qin Ning</last_name>
    <phone>86 27 83662391</phone>
    <email>qning@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Di Wu</last_name>
    <phone>86 27 83662391</phone>
    <email>woody_1984@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>302 Military Hospital of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junliang Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BeiJing YouAn Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinyue Chen, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital Affiliated to AMU</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuqing Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiaji Jiang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine, Zhejiang University</name>
      <address>
        <city>Zhejiang</city>
        <state>Hangzhou</state>
        <zip>Doctor</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qi Xia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Departmen of infectious disease, Xiangya Hospital, Central-south Universit</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deming Tan, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guozhong Gong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuanlong Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Traditional Chinese Medicine,Xiamen Hospital</name>
      <address>
        <city>Shantou</city>
        <state>Xiamen</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qianguo Mao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Wenzhou medical universtiy</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongping Chen, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Qin Ning</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Nucleoside analog</keyword>
  <keyword>Pegylated Interferon</keyword>
  <keyword>Sequential combination therapy</keyword>
  <keyword>HBsAg loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

